ECG - Everus Construction Group, Inc. 0 WATCHERS

&BEAT.-Strategy + Resources + Connections🚨 Richard Ferrari is the co-founder of a venture capital firm (Venture Capital), providing access to capital raising experience and an understanding of how to scale medical startups. • Having commercial sales and marketing veterans on the board (e.g., Ken Nelson) increases the chances that, if …

💎BEAT - Board of Directors .Mr. Ferrari Richard Ferrari has been the Executive Chairman of the Board of Directors of HeartBeam since 2021 and a board member since 2019. He has over 40 years of experience in the medical device industry, serving as the CEO of several startups and as …

Heart Beam $BEAT moon soon🚀 BEAT Could Continue Going Up ✅ 1. The recent news removes a major regulatory risk The company published an update on its FDA regulatory pathway, clarifying that: • The FDA did not reject the product. • The process remains active and on track. • HeartBeam …

Potential Impact on The presence of Apple experts on the team HeartBeam strengthens its expertise in integrating wearables and AI for cardiac monitoring, which could facilitate the development of products compatible with the Apple Watch ecosystem for arrhythmia and ECG detection. This increases the chances of partnerships with Apple or …

HeartBeam Inc🤝FDA. • 🟢⚠️The FDA has signaled a willingness to work with the Company towards a constructive resolution.⚠️🟢 • The Company stands behind the clinical study (VALID-ECG) submitted in support of the application. The study met its clinical endpoints and the Company believes it has a viable argument to address …

AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture * Patent validates AIML’s novel neural-network approach to denoising and mapping ECG signals, powering MaxYield™ and CardioYield™. ‍ * Reinforces competitive advantage as the Company advances commercialization and regulatory pathways. **Toronto, Canada – November 11, 2025** — …

HeartBeam (BEAT)- APPLE 🍏 Richa Gujarati✅ Richa Gujarati has been Senior Vice President of Product at HeartBeam since 2023. Previously, she led Health Products for Apple Watch ⌚️ at Apple, focusing on sensors, apps, and healthcare partnerships. Additional Experts Mohammad Shokoohi-Yekta worked at Apple in data science before joining HeartBeam …

Why This Clinical Test Could Be AIML’s Turning Point AI/ML Innovations ($AIML) has put out a few updates lately, but the SickKids pilot is the one that actually shifts the story for me. Their subsidiary NeuralCloud is now running a **pilot project with The Hospital for Sick Children (SickKids)** to …

AI/ML Subsidiary Neural Cloud Begins Pilot at SickKids to Advance AI-Enabled Pediatric Cardiac Care * ***Pilot Project to Explore AI-Driven ECG Signal Processing and Predictive Deterioration Models in Pediatric Cardiac Care*** **TORONTO, ON / ACCESS Newswire / November 24, 2025 /** NeuralCloud Solutions Inc. ("Neural Cloud"), a subsidiary of **AI/ML …

European markets when the US has a day off… 😂 📉 Is it just me or is it *hilarious* how European markets basically take a nap every single time the US has a holiday? Like… zero movement. Flat as a lake at 5 AM. It’s almost ironic ... Europeans don’t …

"We have engaged in good faith with the agency over a period of two years and have had extremely positive interactions. Together with the agency, we resolved the vast majority of open questions," said Robert Eno, Chief Executive Officer of HeartBeam. The company maintains that its VALID-ECG clinical study met …

BEAT 🟢🤝FDA "We have engaged in good faith with the agency over a period of two years and have had extremely positive interactions. Together with the agency, we resolved the vast majority of open questions," said Robert Eno, Chief Executive Officer of HeartBeam. The company maintains that its VALID-ECG clinical …

From Pilot Projects to Commercial Deals, AIML Just Took the Next Step AI/ML Innovations ($AIML) announced that its subsidiary NeuralCloud has signed a **non-binding commercial term sheet** with Equimetrics to integrate its MaxYield and CardioYield AI ECG tech into equine cardiac-monitoring products expanding beyond human healthcare into **veterinary and elite …

AIML subsidiary NeuralCloud Signs Commercial Term Sheet with Equimetrics to Deploy MaxYield™ and CardioYield™ across Equine Cardiac Monitoring Platforms * ***Agreement expands NeuralCloud’s AI-enhanced ECG signal-processing technology into veterinary health and elite equine performance markets*** ***‍*** * ***Commercial integration expands MaxYield™ and CardioYield™ into V-PRO and S-PRO clinical and performance …

BEAT.In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …

In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …

In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …

In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …

BEAT -Roth Capital 🟢🟢🟢 Roth Capital analysts' key arguments for continued growth in HeartBeam (BEAT) stock include: • Significant potential for 3D ECG technology for remote cardiac monitoring, which addresses a critical healthcare need. • Expected expansion of medical applications for the software following feedback from the FDA, despite the …

BEAT 🟢 Benchmark agency Benchmark justifies its $8 target price for HeartBeam (BEAT) primarily based on the company's progress toward FDA 510(k) clearance for its innovative cardiac monitoring technology. They emphasize the potential for strong revenue growth from the commercial launch of HeartBeam's 3D vector ECG plattorm in preventive and …

HeartBeam,Inc - (ticker BEAT)🟢 HeartBeam is a medical technology company focused on advanced cardiac monitoring, including a portable 3D ECG technology that has received FDA clearance for arrhythmia assessment. HeartBeam's technology is distinct and focuses on 12-lead ECG synthesis and advanced cardiac diagnostics, aiming to transform heart monitoring outside medical …

$BEAT Stumbled across HeartBeam ($BEAT) recently and wanted to throw it out here for discussion because the concept caught my eye. Not financial advice, obviously — just sharing research and seeing what others think. HeartBeam is working on tech aimed at improving how cardiac events are detected outside the hospital …

$BEAT Stumbled across HeartBeam ($BEAT) recently and wanted to throw it out here for discussion because the concept caught my eye. HeartBeam is working on tech aimed at improving how cardiac events are detected outside the hospital setting. What makes them stand out (at least to me) is that they’re …

BEAT -HeartBeam,Inc 🟢 Roth Capital keeps a Buy rating on HeartBeam (BEAT) with a $4✅ price target after the company received a ⚠️“not substantially equivalent” ⚠️letter from the FDA regarding its 510(k) application for its 12-lead electrocardiogram synthesis software. Roth believes the FDA may want the company to use a …

BEAT HeartBeam (BEAT, Financial) continues to hold a Buy rating from Roth Capital with a set price target of $4. The company recently received a "not substantially equivalent" letter from the FDA concerning its 510(k) application for its 12-lead electrocardiogram synthesis software. This feedback suggests that the FDA might be …

The ECG of all of my accounts Here’s how each of my accounts jerked this year thus far. The last one is the performance of all accounts.

So buy companies like ECG.

BEAT (HeartBeam) Anyone saw this stock falling down after NSE letter they Got from FDA? Roth Capital sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said. HeartBeam is …

BEAT 🟢 HeartBeam (BEAT) Receives FDA Feedback; Roth Maintains Optimistic Outlook BEAT guru GuruFocus News 21.11.2025, 23:25:56 Aa Key Takeaways: • HeartBeam (BEAT, Financial) maintains a Buy rating from Roth Capital with a price target of $4. • The FDA has issued a "not substantially equivalent" letter regarding HeartBeam's 12-lead …